New onset diabetes and atypical antipsychotics

Author： Liebzeit K.A.   Markowitz J.S.   Caley C.F.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.11, Iss.1, 2001-02, pp. : 25-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia

By Townsend Lisa   Findling Robert L  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 195-205

Informa Healthcare

Access to resources Recommend Favorite

New Atypical Antipsychotics: Experience and Utility in the Elderly

By Sweet R.A.   Pollock B.G.  

Drugs & Aging, Vol. 12, Iss. 2, 1998-02 ,pp. : 115-127

Adis International

Access to resources Recommend Favorite

The new atypical antipsychotics: a review of pharmacoeconomic studies

By Revicki D.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 249-260

Informa Healthcare

Access to resources Recommend Favorite

Atypical antipsychotics cause diabetes mellitus in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Statins and New-Onset Diabetes

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3657-3664

Bentham Science Publishers

Access to resources Recommend Favorite